Abstract
A controversial study that would expose healthy children to a stimulant should proceed, a Food and Drug Administration (FDA) ethics panel recommended last week. The pediatric ethics subcommittee decided that the study, on attention deficit hyperactivity disorder (ADHD), is ethically acceptable. But it urged sponsors to offer less compensation to enrolled families, saying a proposed $570 payment might unduly influence parents who needed the money.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
